Durham: Fortrea (Nasdaq: FTRE), a global contract research organization, has announced significant changes in its executive team. Oren Cohen, MD, who previously held dual roles as Fortrea's Chief Medical Officer (CMO) and President of Clinical Pharmacology Services (CPS), will now concentrate solely on his responsibilities as CMO. His focus will be on medical strategy, scientific leadership, ethics, and governance oversight across Fortrea's portfolio. In conjunction, Scott Dove, PhD, joins Fortrea as the new President of CPS, tasked with overseeing early clinical development solutions within Fortrea's global network of clinical research units. Both executives will be part of Fortrea's Executive Committee.

According to BERNAMA News Agency, Anshul Thakral, CEO of Fortrea, expressed optimism about the new appointments. Thakral highlighted that with Cohen dedicating himself to the medical and scientific aspects of development, he will engage more deeply with clients early in the scientific dialogue. This engagement is aimed at addressing complex development challenges while maintaining scientific integrity and patient safety. Meanwhile, Dove is expected to bring his technical background in clinical development and operations, along with his proven leadership skills, to strengthen Fortrea's clinical pharmacology segment.